Editorial: Financial Disclosure, Industry Sponsorship, and Integrity in Cancer Research Reporting

.....In short, there is much
left to do to ensure integrity in cancer research reporting. Regrettably,
disclosure alone has not proved sufficient,32 and until such time as
additional safeguards are in place, a credibility gap will likely persist.By
the same token, it is overly cynical to judge a study as tainted simply
because it is funded by industry. As always, evaluating the quality and
integrity of a clinical trial requires careful assessment of the trial’s
design and conduct, using scientific rigor to interpret the results,
accompanied by a healthy dose of common sense.10,33"